Novavax COVID-19疫苗在免疫功能低下患者中的有效性、免疫原性与安全性:一项针对性文献综述
该针对性文献综述检索BIOSIS Previews、Embase、MEDLINE等数据库及公开内容至2024年10月,初检获137篇报告,经筛选纳入10篇出版物,评估Novavax COVID-19疫苗在免疫功能低下人群中的有效性、免疫原性与安全性。总体而言,该疫苗在多样化免疫功能低下人群中具有免疫原性且安全性可耐受;部分结局因疾病和/或合并用药而异。有限的有效性数据提示该疫苗可能有助于保护免疫功能低下人群免于症状性/重症COVID-19,但需更大样本量的进一步研究。
要点
- 初检137篇报告中筛选出10篇出版物,涵盖HIV、多发性硬化、炎症性风湿病、移植受者及血液恶性肿瘤人群。
- Novavax COVID-19疫苗在多样化免疫功能低下人群中具有免疫原性,安全性可耐受。
- 部分结局因疾病、病情和/或合并用药而异;有限有效性数据提示可能有助于预防症状性/重症COVID-19,但需更大样本量研究。
核心结论
- 总体而言,Novavax COVID-19疫苗在多样化免疫功能低下人群中具有免疫原性且安全性可耐受,部分结局因疾病和/或合并用药而异。
- 有限的有效性数据提示该疫苗可能有助于保护免疫功能低下人群免于症状性/重症COVID-19,但需更大样本量的进一步研究。
- 未来研究应纳入疾病特异性人群,以评估个体特征(如疾病状态、合并用药、既往COVID-19疫苗接种)如何影响疫苗反应。
研究设计与样本
- 针对性文献综述,检索BIOSIS Previews®、Embase®、Embase Preprints、MEDLINE®及公开内容,检索截至2024年10月。
- 采用预设的免疫调节疾病/状况及药物相关检索词,初检获137篇报告,经筛选纳入10篇出版物。
- 排除原因包括缺乏疫苗特异性数据(即疫苗接种者有限[<0.2%或n<3]、合并/汇总队列)和/或非免疫功能低下人群。
- 所描述的疾病包括HIV、多发性硬化、炎症性风湿病、移植受者和血液恶性肿瘤。
主要发现
- 总体而言,Novavax COVID-19疫苗在多样化免疫功能低下人群中具有免疫原性且安全性可耐受。
- 部分结局因疾病、病情和/或合并用药而异。
- 有限的有效性数据提示该疫苗可能有助于保护免疫功能低下人群免于症状性/重症COVID-19。
- 检索初检获137篇报告,经筛选后纳入10篇出版物进行综述。
临床怎么用
- 原文未据此给出推荐。
局限性
- 免疫功能低下人群被排除在COVID-19疫苗试验之外,且Novavax COVID-19疫苗的真实世界评估有限,导致数据缺口。
- 有限的有效性数据提示该疫苗可能有助于保护免疫功能低下人群免于症状性/重症COVID-19,但需更大样本量的进一步研究。
- 未来研究应纳入疾病特异性人群,以评估个体特征(如疾病状态、合并用药、既往COVID-19疫苗接种)如何影响疫苗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals who are immunocompromised (IIC) may have impaired infection prevention/resolution, potentially causing increased disease severity, complications, and healthcare-system strain. Exclusion of IIC from COVID-19 vaccine trials and limited real-world Novavax COVID-19 vaccine assessments have resulted in a data gap. This article provides a review of literature on IIC who received the Novavax COVID-19 vaccine. A targeted literature search of BIOSIS Previews®, Embase®, Embase Preprints, MEDLINE®, and publicly available content was performed to identify published clinical data assessing efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in IIC, with predefined terms for immune-modifying diseases/conditions and medications. Identified publications were screened to ensure they described study data from IIC who received the Novavax COVID-19 vaccine. The search (through October 2024) identified 137 reports indicating use of the Novavax COVID-19 vaccine in IIC. Screening resulted in 10 publications for review; exclusionary reasons included a lack of vaccine-specific data (i.e., limited [<0.2% or n < 3] vaccine recipients, pooled/aggregated cohorts) and/or IIC population. Conditions described include HIV, multiple sclerosis, inflammatory rheumatic diseases, transplant recipients, and hematologic malignancies. Overall, the Novavax COVID-19 vaccine was immunogenic and had a tolerable safety profile across diverse populations of IIC; some outcomes varied based on condition, disease, and/or concomitant medication(s). Limited efficacy data indicates that the Novavax COVID-19 vaccine may help protect IIC against symptomatic/severe COVID-19; however, additional studies with larger sample sizes are needed. Future research should include disease-specific populations to assess how individual characteristics (e.g., disease state, concomitant medications, prior COVID-19 vaccination) impact vaccine response.
引用
- Gschwend MH, Marchese AM, Poelaert D, et al. Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review. Vaccine. 2025. PMID: 39892114. doi:10.1016/j.vaccine.2025.126777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。